Author

Alicia M. Michaud

Observed name: Alicia Michaud

Institution: Selecta Biosciences (United States)

Observed institution: Selecta Biosciences (United States)

ORCID: 0000-0003-3109-6386

Observed ORCID: 0000-0003-3109-6386

OpenAlex ID: A5071233186

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

2018 · Amine Meliani, Florence Boisgerault, et al. · Nature Communications · 273

Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles

2021 · Petr O. Ilyinskii, Alicia M. Michaud, et al. · Science Advances · 61

ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia

2021 · Petr O. Ilyinskii, Alicia M. Michaud, et al. · Molecular Therapy — Methods & Clinical Development · 46

Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease

2023 · Takashi Kei Kishimoto, Max Fournier, et al. · Journal of Autoimmunity · 38

Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents

2023 · Petr O Ilyinskii, Christopher Roy, et al. · PNAS Nexus · 20

Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy

2018 · Petr O. Ilyinskii, Grigoriy I. Kovalev, et al. · PLoS ONE · 20

Works count: 6

Citation count: 458

H-index: 6

I10-index: 6